October 8, 2018

Portola’s Cerdulatinib Wins Orphan Drug Designation for Peripheral T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Portola Pharmaceuticals‘ investigative therapy cerdulatinib to treat patients with peripheral T-cell lymphoma (PTCL), the company announced. Orphan drug designation aims to encourage therapies for ... Read more

June 23, 2015August 23, 2016

Novel Drug Shows Promising Results In Lymphoma Treatment

News

During the 13th International Conference on Malignant Lymphoma, held this June in Lugano, Switzerland, promising results were presented relative to a new drug TAK-659, an inhibitor of spleen tyrosine kinase (SYK) with ... Read more